Clinical trial · Observational
The Role of the Muscle-nervous System Interface in Cancer Cachexia
NCT03477721CI-TRIAL-00032228NUMANCANunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sarcopenia is an important component of cachexia associated with cancer, and their high incidence in cancer patients emphasizes the need for a better understanding of its mechanisms, which can result in better therapeutic interventions to reverse this situation and improve the prognosis. Our hypothesis is that the plasma concentration of IL-6 and c-terminal agrin is directly correlated with the loss of muscle mass and development of cachexia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia; Cancer; Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Group with cancer cachexia (CTB)
- description
- For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)
- label
- Group without cancer cachexia (TB)
Primary outcomes (4)
- measure
- Agrin fragment c-terminus CAF in cancer and cancer cachexia
- timeFrame
- 1 month
- description
- To measure the contents of agrin fragment c-terminus (CAF) in plasma of patient with cancer and cancer cachexia.
- measure
- Agrin fragment c-terminus CAF in cancer sarcopenia
- timeFrame
- 1 month
- description
- To analyze correlation between Agrin fragment c-terminus CAF and the lean body mass (CT-scan estimated) of patients with cancer and with cancer cachexia.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * cancer diagnosis Exclusion Criteria: * continuously use of anti-inflammatory medications; * present renal and/or liver failure, * AIDS, * inflammatory bowel disease or chronic inflammatory processes not related to cachexia.
References
Publications (23)
- BACKGROUNDArgiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev. 1997 Sep;17(5):477-98. doi: 10.1002/(sici)1098-1128(199709)17:53.0.co;2-r. No abstract available. PMID 9276862
- BACKGROUNDArgiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care. 2009 Dec;3(4):263-8. doi: 10.1097/SPC.0b013e3283311d09. PMID 19713854
- BACKGROUNDBalkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0. PMID 11229684
- BACKGROUNDBatista ML Jr, Peres SB, McDonald ME, Alcantara PS, Olivan M, Otoch JP, Farmer SR, Seelaender M. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine. 2012 Jan;57(1):9-16. doi: 10.1016/j.cyto.2011.10.008. Epub 2011 Nov 17. PMID 22099872
- BACKGROUNDBelizario JE, Fontes-Oliveira CC, Borges JP, Kashiabara JA, Vannier E. Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6. Springerplus. 2016 May 13;5:619. doi: 10.1186/s40064-016-2197-2. eCollection 2016. PMID 27330885
- BACKGROUNDEvans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr. 2008 Dec;27(6):793-9. doi: 10.1016/j.clnu.2008.06.013. Epub 2008 Aug 21. PMID 18718696
- BACKGROUNDFan Y, Mao R, Yang J. NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013 Mar;4(3):176-85. doi: 10.1007/s13238-013-2084-3. Epub 2013 Mar 13. PMID 23483479